Galmed Pharmaceuticals
GLMD
12 hedge funds and large institutions have $57.6K invested in Galmed Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 3 closing their positions.
1% less ownership
Funds ownership: 1.38% → 0.38% (-1%)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
80% less capital invested
Capital invested by funds: $286K → $57.6K (-$229K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$6.13K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$847 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$73.1K |
| 2 |
Morgan Stanley
New York
|
-$56.5K |
| 3 |
Walleye Capital
New York
|
-$27.6K |
| 4 |
Two Sigma Investments
New York
|
-$10.7K |
| 5 |
Two Sigma Advisers
New York
|
-$8.32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CH
1
CVI Holdings
Wilmington,
Delaware
| $24.5K | -$73.1K | -16,215 | -72% |
|
|
2
Walleye Capital
New York
| $13.8K | -$27.6K | -6,116 | -64% |
|
|
3
Two Sigma Advisers
New York
| $7.71K | -$8.32K | -1,847 | -50% |
|
|
TSS
4
Two Sigma Securities
New York
| $5.65K | +$6.13K | +1,359 | New |
|
|
5
Morgan Stanley
New York
| $5.02K | -$56.5K | -12,537 | -91% |
|
|
6
UBS Group
Zurich,
Switzerland
| $782 | +$847 | +188 | New |
|
7
Wells Fargo
San Francisco,
California
| $71 | – | – | – |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $58 | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $18 | – | – | – |
|
|
AF
10
Allworth Financial
Folsom,
California
| $6 | – | – | – |
|
|
EWP
11
Elevation Wealth Partners
Santa Rosa,
California
| $3 | – | – | – |
|
|
12
Two Sigma Investments
New York
| – | -$10.7K | -1,960 | Closed |
|
13
Citadel Advisors
Miami,
Florida
| – | -$5.12K | -938 | Closed |
|
|
BCM
14
Bourgeon Capital Management
Darien,
Connecticut
| – | -$16 | -3 | Closed |
|
GLMD Hedge Fund Activity: Q1 2024 in Review
12 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2024, worth a combined $57.6K — down 80% from $286K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GLMD and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 0 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $6.13K. The largest seller was CVI Holdings, cutting an estimated $73.1K.
- 12 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2024, down from 13 in Q4 2023.
- Funds reported $57.6K of Galmed Pharmaceuticals stock for Q1 2024, down 80% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q1 2024 was Two Sigma Securities, an estimated $6.13K added.
- The largest Galmed Pharmaceuticals seller in Q1 2024 was CVI Holdings, an estimated $73.1K sold.
Based on aggregated 13F filings for Q1 2024.